Cardiology Medical News about Antiplatelet Agents

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death

3. The Job Market for 2008-2009: Compensation

4. Renal Artery Stenosis

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Novel Antiplatelet Agents in Development: Prasugrel, Ticagrelor, and Cangrelor and Beyond
American Journal of Therapeutics, 09/29/09

Shalito I et al. – The application of current evidence–based therapy including the administration of low–dose aspirin and standard of care with clopidogrel proved to exhibit absolute mortality reduction in the randomized clinical trials International Study for Infarct Survival and Clopidogrel and Metoprolol in Myocardial Infarction Trial among patients after acute vascular events. In this review, the authors will focus on the developmental efforts with regard to the experimental agents such as adenosine diphosphate receptor blockers (prasugrel, ticagrelor, and cangrelor) and platelet glycoprotein VI adhesion antagonist.

<< Previous
Cardiovascular Manifestations of Insulin Resistance

Next >>
Coronary calcium score and computed tomography coronary...